These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 24894561)

  • 1. Synthesis of new verapamil analogues and their evaluation in combination with rifampicin against Mycobacterium tuberculosis and molecular docking studies in the binding site of efflux protein Rv1258c.
    Singh K; Kumar M; Pavadai E; Naran K; Warner DF; Ruminski PG; Chibale K
    Bioorg Med Chem Lett; 2014 Jul; 24(14):2985-90. PubMed ID: 24894561
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular modelling and simulation studies of the Mycobacterium tuberculosis multidrug efflux pump protein Rv1258c.
    Cloete R; Kapp E; Joubert J; Christoffels A; Malan SF
    PLoS One; 2018; 13(11):e0207605. PubMed ID: 30475855
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Piperine as an inhibitor of Rv1258c, a putative multidrug efflux pump of Mycobacterium tuberculosis.
    Sharma S; Kumar M; Sharma S; Nargotra A; Koul S; Khan IA
    J Antimicrob Chemother; 2010 Aug; 65(8):1694-701. PubMed ID: 20525733
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Morphological changes and differentially expressed efflux pump genes in Mycobacterium tuberculosis exposed to a rifampicin and verapamil combination.
    Caleffi-Ferracioli KR; Amaral RC; Demitto FO; Maltempe FG; Canezin PH; Scodro RB; Nakamura CV; Leite CQ; Siqueira VL; Cardoso RF
    Tuberculosis (Edinb); 2016 Mar; 97():65-72. PubMed ID: 26980498
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modulatory effects of verapamil in rifampicin activity against Mycobacterium tuberculosis.
    Caleffi-Ferracioli KR; Cardoso RF; de Souza JV; Murase LS; Canezin PH; Scodro RB; Ld Siqueira V; Pavan FR
    Future Microbiol; 2019 Feb; 14():185-194. PubMed ID: 30648892
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro activity of rifampicin and verapamil combination in multidrug-resistant mycobacterium tuberculosis.
    Demitto Fde O; do Amaral RC; Maltempe FG; Siqueira VL; Scodro RB; Lopes MA; Caleffi-Ferracioli KR; Canezin PH; Cardoso RF
    PLoS One; 2015; 10(2):e0116545. PubMed ID: 25689777
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intramacrophage Mycobacterium tuberculosis efflux pump gene regulation after rifampicin and verapamil exposure.
    Canezin PH; Caleffi-Ferracioli KR; Scodro RBL; Siqueira VLD; Pavan FR; Barros ILE; Cardoso RF
    J Antimicrob Chemother; 2018 Jul; 73(7):1770-1776. PubMed ID: 29579201
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Verapamil, and its metabolite norverapamil, inhibit macrophage-induced, bacterial efflux pump-mediated tolerance to multiple anti-tubercular drugs.
    Adams KN; Szumowski JD; Ramakrishnan L
    J Infect Dis; 2014 Aug; 210(3):456-66. PubMed ID: 24532601
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The human proton pump inhibitors inhibit
    Lake MA; Adams KN; Nie F; Fowler E; Verma AK; Dei S; Teodori E; Sherman DR; Edelstein PH; Spring DR; Troll M; Ramakrishnan L
    Proc Natl Acad Sci U S A; 2023 Feb; 120(7):e2215512120. PubMed ID: 36763530
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel C-3-(N-alkyl-aryl)-aminomethyl rifamycin SV derivatives exhibit activity against rifampicin-resistant Mycobacterium tuberculosis RpoB
    Zloh M; Gupta M; Parish T; Brucoli F
    Eur J Med Chem; 2021 Dec; 225():113734. PubMed ID: 34418786
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The EU approved antimalarial pyronaridine shows antitubercular activity and synergy with rifampicin, targeting RNA polymerase.
    Mori G; Orena BS; Franch C; Mitchenall LA; Godbole AA; Rodrigues L; Aguilar-Pérez C; Zemanová J; Huszár S; Forbak M; Lane TR; Sabbah M; Deboosere N; Frita R; Vandeputte A; Hoffmann E; Russo R; Connell N; Veilleux C; Jha RK; Kumar P; Freundlich JS; Brodin P; Aínsa JA; Nagaraja V; Maxwell A; Mikušová K; Pasca MR; Ekins S
    Tuberculosis (Edinb); 2018 Sep; 112():98-109. PubMed ID: 30205975
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efflux pumps of Mycobacterium tuberculosis play a significant role in antituberculosis activity of potential drug candidates.
    Balganesh M; Dinesh N; Sharma S; Kuruppath S; Nair AV; Sharma U
    Antimicrob Agents Chemother; 2012 May; 56(5):2643-51. PubMed ID: 22314527
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efflux pump inhibition by 11H-pyrido[2,1-b]quinazolin-11-one analogues in mycobacteria.
    Sen T; Neog K; Sarma S; Manna P; Deka Boruah HP; Gogoi P; Singh AK
    Bioorg Med Chem; 2018 Sep; 26(17):4942-4951. PubMed ID: 30190182
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In Vitro Evaluation of Inhalable Verapamil-Rifapentine Particles for Tuberculosis Therapy.
    Parumasivam T; Chan JG; Pang A; Quan DH; Triccas JA; Britton WJ; Chan HK
    Mol Pharm; 2016 Mar; 13(3):979-89. PubMed ID: 26808409
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efflux Attenuates the Antibacterial Activity of Q203 in Mycobacterium tuberculosis.
    Jang J; Kim R; Woo M; Jeong J; Park DE; Kim G; Delorme V
    Antimicrob Agents Chemother; 2017 Jul; 61(7):. PubMed ID: 28416541
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular modelling and competitive inhibition of a Mycobacterium tuberculosis multidrug-resistance efflux pump.
    Scaini JLR; Camargo AD; Seus VR; von Groll A; Werhli AV; da Silva PEA; Machado KDS
    J Mol Graph Model; 2019 Mar; 87():98-108. PubMed ID: 30529931
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Carvacrol activity & morphological changes in Mycobacterium tuberculosis.
    Nakamura de Vasconcelos SS; Caleffi-Ferracioli KR; Hegeto LA; Baldin VP; Nakamura CV; Stefanello TF; Freitas Gauze G; Yamazaki DA; Scodro RB; Siqueira VL; Cardoso RF
    Future Microbiol; 2018 Jun; 13():877-888. PubMed ID: 29877104
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comprehensive phenotypic characterization of rifampicin resistance mutations in Salmonella provides insight into the evolution of resistance in Mycobacterium tuberculosis.
    Brandis G; Pietsch F; Alemayehu R; Hughes D
    J Antimicrob Chemother; 2015 Mar; 70(3):680-5. PubMed ID: 25362573
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New Verapamil Analogs Inhibit Intracellular Mycobacteria without Affecting the Functions of Mycobacterium-Specific T Cells.
    Abate G; Ruminiski PG; Kumar M; Singh K; Hamzabegovic F; Hoft DF; Eickhoff CS; Selimovic A; Campbell M; Chibale K
    Antimicrob Agents Chemother; 2015 Dec; 60(3):1216-25. PubMed ID: 26643325
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis and antimycobacterial activities of some new thiazolylhydrazone derivatives.
    Ozadali K; Tan OU; Yogeeswari P; Dharmarajan S; Balkan A
    Bioorg Med Chem Lett; 2014 Apr; 24(7):1695-7. PubMed ID: 24631185
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.